Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.

JACC. Heart failure - 1 Nov 2021

Sperry Brett W, Hanna Mazen, Shah Sanjiv J, Jaber Wael A, Spertus John A

Abstract excerpt

OBJECTIVES: This study investigated an enriched cohort of patients with heart failure and preserved ejection fraction (HFpEF) in TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) with an echocardiographic phenotype of cardiac amyloidosis. BACKGROUND: There is a high prevalence of increased interventricular septal (IVS) thickness and decreased mitral annular systolic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis
Share to Echocardiography

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Heart Failure

Share to Phenotype

Share to Stroke Volume

Share to Treatment Outcome

Source

Identifiers

PMID: 34509404
DOI: 10.1016/j.jchf.2021.06.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.PMID 34509404Read ↗

Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.Semantic proximity Read ↗

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment.Semantic proximity Read ↗

Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.Semantic proximity Read ↗

Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction.Semantic proximity Read ↗

Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.Semantic proximity Read ↗

Enrichment for Cases of African-American Patients with Pathogenic <i>TTR</i> V142I Variant in the TOPCAT TrialSemantic proximity Read ↗

Men and women differ with regard to the prevalence, phenotype, and prognosis of wild-type transthyretin amyloid cardiomyopathySemantic proximity Read ↗

Amyloid heart disease: genetics translated into disease-modifying therapySemantic proximity Read ↗

Small Hearts, Big Clues: Amyloidosis in WomenSemantic proximity Read ↗

Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure.Semantic proximity Read ↗

Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes.Semantic proximity Read ↗

Pathophysiology and treatment of cardiac amyloidosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.